Physician profile
Robert C Brock
NPI 1891767695
$1,645.55
in general payments reported to CMS, 2019-2025
17 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.38 · 2022: $73.24 · 2023: $582 · 2024: $573 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,557.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $356.04 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $225.55 | 2023-2024 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $220.69 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $176.18 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $119.27 | 2024-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $117.72 | 2023-2025 | Qulipta, Viberzi, Linzess |
| Pfizer INC. | $107.04 | 2023-2025 | |
| Exact Sciences Corporation | $71.75 | 2024-2025 | Cologuard Collection Kit |
| Vertex Pharmaceuticals Incorporated | $45.28 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.23 | 2023-2024 | Ofev |
| Novartis Pharmaceuticals Corporation | $33.42 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $32.88 | 2024 | Uptravi, Opsumit |
| Astellas Pharma US INC | $27.32 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $22.86 | 2023 | |
| Gilead Sciences, INC. | $20.46 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $16.24 | 2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $13.62 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Brock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.